Journals / Akdeniz Tıp Dergisi / 2021 / Cilt: 7 - Sayı: 2

Comparison of Non-invasive Fibrosis Scoring Methods with Liver Biopsy in Chronic Hepatitis B Patients

Kronik Hepatit B Hastalarında Non-invaziv Fibrozis Skorlama Yöntemlerinin Karaciğer Biyopsisi ile Karşılaştırılması

Pages
283–288
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe that this study, in which we present our data in detail, will contribute to meta-analysis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In recent years, many studies have been conducted on non-invasive diagnostic methods to evaluate fibrosis in patients with chronic hepatitis B (CHB).
📊
Key Findings & Data:Material and Methods: Twenty patients who were followed up in our hospital for infectious diseases outpatient clinic between April 2017 and April 2019 due to CHB and who underwent percutaneous liver biopsy in the interventional radiology unit were included in the study.
💡
Conclusion & Impact:We believe that this study, in which we present our data in detail, will contribute to meta-analysis.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:APRI · FIB-4 · Karaciğer biyopsisi

Abstract

Objective: In recent years, many studies have been conducted on non-invasive diagnostic methods to evaluate fibrosis in patients with chronic hepatitis B (CHB). However, liver biopsy is still considered the gold standard. In this study, we aimed to present the biopsy results and non-invasive fibrosis scoring findings of CHB patients and to determine biopsy in terms of starting treatment. Material and Methods: Twenty patients who were followed up in our hospital for infectious diseases outpatient clinic between April 2017 and April 2019 due to CHB and who underwent percutaneous liver biopsy in the interventional radiology unit were included in the study. Demographic features, alanine aminotransferase, aspartate aminotransferase, HBV-DNA levels, platelet counts were examined. APRI (AST to Platelet Ratio Index) and FIB-4 (Fibrosis-4) values were calculated. Results: The mean fibrosis score of the patients was 2±0.67, the average histological activity score (HAI) was 6.79±2.49, and the mean platelet counts were 235.35±54.84 10³ / μL. The average of APRI (AST to Platelet Ratio Index) value was calculated as 0.53 ± 0.36 and the average of FIB-4 (Fibrosis-4) value was calculated as 0.97±0.51. In statistical analysis, there was no significant correlation between HAI - APRI, HAI - FIB-4, fibrosis score - APRI, fibrosis score - FIB-4 (P values 0.473, 0.595, 0.078, 0.718, respectively). Conclusion: In our study, no correlation with the degree of fibrosis was detected in the statistical evaluation in terms of APRI and FIB-4 values. We think this is due to the small number of our cases. We believe that this study, in which we present our data in detail, will contribute to meta-analysis.

Özet

Amaç: Son yıllarda kronik hepatit B’li (KHB) hastalarda fibrozisi değerlendirmek amacıyla noninvaziv tanı yöntemleri üzerinde pek çok çalışma yapılmıştır. Ancak halen karaciğer biyopsisi altın standart olarak kabul edilmektedir. Bu çalışmada KHB hastalarının biyopsi sonuçlarını ve non-invaziv fibrozis skorlama bulgularını karşılaştırmayı ve bunların ışığında tedaviye başlama açısından biyopsiyi değerlendirmeyi amaçladık. Gereç ve Yöntemler: Hastanemiz enfeksiyon hastalıkları polikliniğinde Nisan 2017-Nisan 2019 tarihleri arasında kronik hepatit B nedeniyle takip edilen ve girişimsel radyoloji ünitesinde perkütan karaciğer biyopsisi yapılan 20 hasta çalışma kapsamına alındı. Hastaların, demografik özellikleri, alanin aminotransferaz, aspartat aminotransferaz, HBV-DNA düzeyleri, trombosit sayıları incelendi. APRI (AST to Platelet Ratio Index) ve FIB-4 (Fibrosis-4) değerleri hesaplandı. Bulgular: Hastaların ortalama fibrozis skoru 2±0,67, ortalama histolojik aktivite skoru (HAİ) 6,79±2,49, ortalama trombosit sayıları 235,35±54,84 10³/μL olarak bulundu. APRI değerinin ortalaması 0,53±0,36, FIB-4 değerinin ortalaması ise 0,97±0,51 olarak hesaplandı. Yapılan istatistiksel analizde HAİ - APRI, HAİ - FIB-4, fibrozis skoru – APRI, fibrozis skoru – FIB-4 arasında anlamlı korelasyon saptanmadı (P değerleri sırasıyla 0,473, 0,595, 0,078, 0,718). Sonuç: Bizim çalışmamızda APRI ve FIB-4 değerleri açısından yapılan istatistiksel değerlendirmede fibrozis derecesi ile korelasyon saptanamamıştır. Bunun vaka sayımızın az olmasından kaynaklandığını düşünüyoruz. Verilerimizi detaylı olarak sunduğumuz bu çalışmamızın meta analizlere katkı sunacağı kanaatindeyiz.

🔖

Cite This Article

KESİMAL, U., DURMAZ, Ş. Ö. (2022). Comparison of Non-invasive Fibrosis Scoring Methods with Liver Biopsy in Chronic Hepatitis B Patients. Akdeniz Tıp Dergisi, Cilt: 7 - Sayı: 2, 283–288. https://ajindex.com/articles/434258

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386(1003): 1546- 55
  2. Papatheodoridis G, Zoulim F, Tacke F. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017 67(2) 370-98
  3. Bravo A, Sheth SG, Chopra S. Liver biopsy. N Eng J Med 2001; 344: 495-500
  4. Crespo J. The art of predicting fibrosis in hepatitis C. Rev Esp Enferm Dig 2006; 98: 153-60
  5. Mardini H, Record C. Detection of assessment and monitoring of hepatic fibrosis: Biochemistry or biopsy?. Ann Clin Biochem 2005; 42: 441-7
  6. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective studyon 68.276 biopsies. J Hepatol 1986; 2: 165-73
  7. Bedossa P, Dargere D, Paradşs V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1356-8
  8. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5
  9. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheurer PJ. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994; 19: 1513-20
  10. Solak-Grassie S, Gözütok F, Coşkun B, Dural S, Atakent ŞD. Evaluation of HBeAg-negative chronic hepatitis B patients who had undergone liver biopsy in accordance with the guidelines. Klimik Derg 2018; 31(1): 37-40
  11. Tuna N, Yahyaoğlu M, Öztürk G, Öğütlü A, Çalica UA, Durmaz Y, Gözdaş HT, Güçlü E, Karabay O. Liver biopsy experience. Viral Hepatitis Journal 2012; 18(3): 115-9
  12. Erdem H. Karaciğer iğne biyopsisi. Ed: Tabak F, Tosun S. Viral Hepatit 2013. Ankara:Viral Hepatitle Savaşım Derneği, 2013: 13-23
  13. Paulson EK and Nelson RC. Techniques of Percutaneous Tissue Acquisition. In: Textbook of Gastrointestinal Radiology. Ed: Gore RMG, Levine MS. Second edition. W.B. Saunders Company 1219-33
  14. Smith EH. Complications of percutaneous abdominal fine-needle biopsy: a review. Radiology 1991; 178: 253-8
  15. Picciniono F, Sagnelli E, Pasquela G, Giusti G. Complications after percutaneous liver biopsy. J Hepatol 1986; 2: 165-73
  16. Büyükkaya R, Oktay M, Büyükkaya A, Öztürk B, Özel MA, Beşir FH, Yazıcı B. Kronik Viral Hepatitli Hastalarda Ultrasonogr